Pirarubicin is an anthracycline that has anticancer activity.1 It interacts with topoisomerase II to inhibit DNA replication. Pirarubicin inhibits the growth of human HeLa and C33A cervical, as well as T-24 bladder cancer cells (IC50s = 29, 52, and 36 ng/ml, respectively).2 It inhibits the growth of human Huh7 and MHCC97H liver cancer cells (IC50s = 0.159 and 0.374 μM, respectively).3 Pirarubicin also inhibits the growth of M5076 mouse ovarian cancer cells in vitro (IC50 = 0.366 μM) and in vivo in a mouse allograft model when administered at a dose of 2 mg/kg for four days.4
1.Monneret, C.Recent developments in the field of antitumour anthracyclinesEur. J. Med. Chem.36(6)483-493(2001) 2.Tsuchiya, K.S., Ishii, T., Ikeno, S., et al.Inhibition of anchorage-independent growth of tumor cells by IT-62-B, a new anthracyclineJ. Antibiot. (Tokyo)50(10)853-859(1997) 3.Huang, H., Chen, T., Zhou, Y., et al.RIPK1 inhibition enhances pirarubicin cytotoxic efficacy through AKT-P21-dependent pathway in hepatocellular carcinomaInt. J. Med. Sci.15(14)1648-1657(2018) 4.Sugiyama, T., Sadzuka, Y., Nagasawa, K., et al.Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicinJpn. J. Cancer Res.90(7)775-780(1999)
















